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Abstract
Introduction: In anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV), persistent
inflammation within the vessel wall suggests perturbed neutrophil trafficking leading to accumulation of
activated neutrophils in the microvascular compartment. CXCR1 and CXCR2, being major chemokine receptors
on neutrophils, are largely responsible for neutrophil recruitment. We speculate that down-regulated
expression of CXCR1/2 retains neutrophils within the vessel wall and, consequently, leads to vessel damage.
Methods: Membrane expression of CXCR1/2 on neutrophils was assessed by flow cytometry. Serum levels of
interleukin-8 (IL-8), tumor necrosis factor alpha (TNF-a), angiopoietin 1 and angiopoietin 2 from quiescent and
active AAV patients and healthy controls (HC) were quantified by ELISA. Adhesion and transendothelial migration
of isolated neutrophils were analyzed using adhesion assays and Transwell systems, respectively.
Results: Expression of CXCR1 and CXCR2 on neutrophils was significantly decreased in AAV patients compared to
HC. Levels of IL-8, which, as TNFa, dose-dependently down-regulated CXCR1 and CXCR2 expression on neutrophils
in vitro, were significantly increased in the serum of patients with active AAV and correlated negatively with
CXCR1/CXCR2 expression on neutrophils, even in quiescent patients. Blocking CXCR1 and CXCR2 with repertaxin
increased neutrophil adhesion and inhibited migration through a glomerular endothelial cell layer.
Conclusions: Expression of CXCR1 and CXCR2 is decreased in AAV, potentially induced by circulating
proinflammatory cytokines such as IL-8. Down-regulation of these chemokine receptors could increase neutrophil
adhesion and impair its migration through the glomerular endothelium, contributing to neutrophil accumulation
and, in concert with ANCA, persistent inflammation within the vessel wall.
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AAV comprises granulomatosis with polyangiitis (GPA),
microscopic polyangiitis (MPA) and Churg Strauss syn-
drome (CSS), which share a spectrum of clinical mani-
festations reflecting necrotizing damage to small- and
medium-sized vessels [1,2]. A role for neutrophils as
effector cells in AAV is supported by a large body of
evidence from in vitro and in vivo studies. After being
primed by proinflammatory cytokines such as TNF-a,
neutrophils can be activated by ANCA and release oxy-
gen radicals and proteolytic enzymes, which have been
shown to lyse endothelial cells in in vitro co-cultures
[3,4]. In vivo, neutrophil accumulation in glomeruli has
been observed in the early phase of crescentic glomeru-
lonephritis and neutrophil depletion could completely
prevent disease development in experimental models [5].
Migration of neutrophils is largely regulated by the con-
centration gradient of CXC-chemokines which contain a
glutamic acid-leucine-arginine (ELR
+)m o t i fa n da r et h e
most powerful chemoattractants for neutrophils. Interleu-
kin 8 (IL-8) is the most potent member of the CXC family
with high affinity for both of its receptors, CXCR1 and
CXCR2, which are co-expressed on the membrane of neu-
trophils. Thus, binding of IL-8 to CXCR1/2 is a major ele-
ment in neutrophil recruitment [6].
Neutrophils function in immune surveillance. Their
activation, in terms of degranulation and oxidative
burst, arms neutrophils with microbicidal activity, which
normally appears only after they have migrated from the
circulation and reach inflamed tissues [7]. However, in
the pathology of AAV, necrotizing damage within the
v e s s e lw a l ls u g g e s t st h a tA N C A - m e d i a t e dn e u t r o p h i l
activation is already triggered during neutrophil recruit-
ment. This may be caused by impaired neutrophil traf-
ficking retaining activated neutrophils within the
microvascular compartment.
Although consensus is still lacking whether ANCA
bind to neutrophils in suspension, it has been well
demonstrated that membrane bound-proteinase 3 (PR3)
o nn e u t r o p h i l si ss i g n i f i c a n tly upregulated during neu-
trophil adhesion, and full neutrophil activation not only
requires ANCA-antigen cross-linking but also adherence
of neutrophils [8-11]. Here, we hypothesize that IL-8-
CXCR1/CXCR2-mediated neutrophil recruitment is
hampered in AAV, which leads to firm adhesion of neu-
trophils to the endothelium without further transmigra-
tion. Retained neutrophils within the microvascular
compartment may be activated by ANCA, which will
result in persistent inflammation of the vessel wall. To
test this hypothesis, we investigated expression profiles
of CXCR1 and CXCR2 on neutrophils in patients with
AAV, related expression to levels of chemoattractants,
and analyzed effects on transmigration.
Materials and methods
Patients and healthy controls
For measurement of CXCR1 and CXCR2 expression, 37
patients with quiescent AAV and 5 AAV patients with
active disease were recruited from our out-patient clinic.
Thirty healthy donors recruited from laboratory person-
nel were included as a normal control population. Char-
acteristics of patients and controls are summarized in
Table 1.
A diagnosis of granulomatosis with polyangiitis (GPA),
Churg Strauss syndrome (CSS) or microscopic polyan-
giitis (MPA) was based on the Chapel Hill definitions
[12]. ANCA specificity for PR3 or myeloperoxidase
(MPO) was determined by capture ELISA. Patients in
remission were without treatment. Treatment of active
patients is listed in Table 1. Disease severity was quanti-
fied using the Birmingham Vasculitis Activity Score
(BVAS).
Table 1 Characteristics of patients and controls.
Characteristics Number (%) or mean (range)
HC
(n = 30)
AAV
Remission
(n = 37)
Active
a
(n =5 )
Active
b
(n = 18)
Male 17 (57) 25 (68) 3 (60) 14 (78)
Age (years) 45 (28-64) 57 (26-84) 58 (47-68) 58 (32-81)
Diagnosis
GPA 26 4 13
MPA 9 1 5
NCGN 2 0 0
ANCA-specificity
PR3 24 (65) 4 (80) 13 (72)
MPO 13 (35) 1 (20) 5 (28)
Organ involvement
ENT 0 4 (80) 5 (28)
Eye 0 1 (20) 4 (22)
Lung 0 4 (80) 8 (44)
Kidney 0 2 (40) 13 (72)
Skin 0 1 (20) 0
Nervous system 0 1 (20) 2 (11)
BVAS, median (range) 0 14.8 (6-26) 17.5 (6-33)
Treatment
MMF 0 1 (20) 3 (17)
CYC 0 4 (80) 11 (61)
Prednisolon 0 4 (80) 16 (89)
AAV, ANCA-associated vasculitides; ANCA, anti-neutrophil cytoplasmic
autoantibody; BVAS, Birmingham Vasculitis Activity Score; CYC,
cyclophosphamide; ENT, ear, nose and throat; GPA, granulomatosis with
polyangiitis; HC, healthy control; MMF, mycophenolate mophetil; MPA,
microscopic polyangiitis; MPO, myeloperoxidase; NCGN, necrotizing crescentic
glomerulonephritis; PR3, proteinase 3;
aActive patients included in CXCR1 and
CXCR2 measurement by flow cytometry.
bActive patients included in cytokine
profiling by ELISA.
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collected for cytokine profiling. For patients in remis-
sion, samples were drawn on the same day for CXCR1/2
measurement and cytokine testing. For patients who
were in remission but had suffered from active disease
before (n = 18), serum samples from active disease were
retrieved from a stored serum bank. All sera were stored
at -80°C before testing.
All subjects gave their informed consent and the study
was approved by the hospital medical ethical committee.
Antibodies used for flow cytometry
Peridin chlorophyll protein (PerCP)/Cy5.5-conjugated
anti-CD14 (HCD14; Biolegend, San Diego, CA, USA)
was used to discriminate neutrophils from monocytes in
whole blood staining. Phycoerythrin (PE)-conjugated
anti-CD181 (CXCR1, 5A12; BD Bioscience, Alphen aan
de Rijn, The Netherlands), allophycocyanin (APC)-con-
j u g a t e da n t i - C D 1 8 2( C X C R 2 ,6 C 6 ;B DB i o s c i e n c e ,
Alphen aan de Rijn, The Netherlands) and fluorescein
isothiocyanate (FITC)-conjugated anti-CD177 (NB1,
MEM166; abCAM, Cambridge, UK) were used to detect
membrane expression of CXCR1, CXCR2 and CD177,
respectively. Irrelevant antibodies of the same isotype
were used as negative controls.
Cell culture
Human conditionally immortalized glomerular endothe-
lial cells (CiGEnC) [13] were cultured in endothelial
growth medium 2-microvascular (EGM2-MV; Cambrex-
Lonza, Breda, The Netherlands) containing 5% FCS and
growth factors, without vascular endothelial growth fac-
tor (VEGF), as supplement. CiGEnC up to passage 40
were propagated at 33°C to keep cells in a proliferative
state. Experiments were carried out on cells that had
grown into a confluent monolayer and had been incu-
bated for 5 days at 37°C in order to acquire a non-pro-
liferative/quiescent phenotype.
Neutrophil isolation and stimulation
Neutrophils were isolated from peripheral blood accord-
ing to routine procedures as described previously [14].
Briefly, heparinized venous blood was centrifuged on
Lymphoprep (Axis-Shield, Oslo, Norway). Contaminat-
ing erythrocytes were lysed with ice-cold ammonium
chloride buffer. Afterwards, cells were washed with cold
Hanks’ balanced salt solution (HBSS) without Ca
2+/Mg
2
+ (HBSS
-/-) and resuspended in HBSS with Ca
2+/Mg
2+
(HBSS
+/+; GIBCO/Life Technologies, Breda, The Neth-
erlands) to obtain 10
7 cells/ml.
Where indicated, cells were incubated with serial
doses of interleukin-8 (IL-8; R&D Systems, Minneapolis,
MN USA), angiopoietin-1 (ANGPT-1; R&D Systems,
Minneapolis, MN USA), angiopoietin-2 (ANGPT-2;
R&D Systems, Minneapolis, MN USA), recombinant
human tumor necrosis factor-a (rhTNF-a;R & DS y s -
tems, Minneapolis, MN USA) or repertaxin (Sigma-
Aldrich, ST. Louis, MO USA) at 37°C for 30 minutes.
Non-stimulated cells were incubated with control med-
ium under the same condition.
Membrane staining of neutrophils for flow cytometry
Membrane expression of CXCR1, CXCR2 and CD177
on neutrophils was assessed by flow cytometry. Accord-
ing to the manufacturer’s instructions, 100 μlo fw h o l e
blood from patients and controls or 10
6 of purified neu-
trophils after in vitro stimulation were incubated with
antibodies at room temperature, in the dark, for 15 min-
utes, followed by fixation and lysing of erythrocytes with
20 × volume of Fluorescence Activated Cell Sorting
(FACS) lysing solution (BD Bioscience, San Jose, CA,
USA). Fluorescence intensity was measured by FACS
Calibur (Becton Dickinson Immunocytometry Systems,
Mountain View, CA, USA) and calibrated using Cell-
Quest™ software (Becton Dickinson). Results were ana-
lyzed using the Win-List software package (Verity
Software House, Topsham, ME, USA). Mean fluores-
cence intensity (MFI) of 5.10
4 counted cells was mea-
sured in each sample. Neutrophils were gated as
forward scatter
high (FSC
high)-side scatter
high (SSC
high)-
CD14
low cells. Expression levels were presented as MFI
corrected for nonspecific binding of isotype control anti-
bodies on neutrophils from the same donor.
MPO activity assay
Numbers of adherent or migrated neutrophils in adhe-
sion or migration assay were quantified by myeloperoxi-
dase (MPO) activity assay [15]. Briefly, cells were lysed
with 0.5% Triton-X-100 at 4°C for 20 minutes and acidi-
fied by adding 1 M citrate buffer (pH = 4.2, 50 μl/1 ml
of cell lysate) just prior to the reaction. Aliquots (75 μl)
from each sample were transferred into wells of a flat-
bottomed 96-well plate. 2.2’-azino-bis-3-ethylbenzothia-
zoline-6-sulfonic acid (ABTS) at a concentration of
0.05% in 100 mM citrate with 0.03% H2O2 was loaded
in an equal volume as substrate for MPO. After the
reaction, OD405 was measured using an ELISA plate
reader. Numbers of neutrophils in each well were deter-
mined as based on standards generated from known
concentrations of neutrophils from the same isolation.
Neutrophil adhesion
Neutrophil adhesion to endothelial monolayers was
quantified by adhesion assay as described previously
with modifications [16]. CiGEnCs were seeded in 24-
well plates and allowed to proliferate to confluence. Cell
monolayers were carefully washed with HBSS
+/+ and sti-
mulated with 10 ng/ml TNF-a at 37°C for 4 hours.
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6
neutrophils were loaded. Where indicated, neutrophils
were pretreated with serial doses of IL-8, TNF-a or
repertaxin which is a noncompetitive allosteric inhibitor
of CXCR1 and CXCR2 [17]. After incubation of
endothelial cells with neutrophils at 37°C for 30 min-
utes, loosely adherent or non-adherent neutrophils were
washed off with HBSS
-/- and the endothelial monolayers
plus adherent neutrophils were lysed in 0.5% Triton-X-
100. All experiments were run in duplicate. The num-
bers of neutrophils were quantified, as described above,
by MPO activity assay.
Neutrophil migration
Transwell inserts (Corning, NY, USA), with 3.0 μm
pores in 12-well plates, were precoated with CiGEnCs.
Confluence of the endothelial monolayers was deter-
mined by continued monitoring of trans-endothelial
electrical resistance (TEER) [13] which plateaued at 20
to 25 Ω on the 5
th day after seeding. Histological stain-
ing of the membrane showed that the formation of
monolayers on inserts required 6 × 10
4 cells and 5 days
of culture. Therefore, all the Transwell inserts were
coated with CiGEnCs following this standard procedure.
Isolated neutrophils from healthy donors were preincu-
bated with repertaxin, IL-8 or TNF-a,a n d1 . 1 0
6 cells
were loaded in the upper chamber and 10 ng/ml of IL-
8, which showed optimal efficiency as a chemoattactant
in titration in preliminary experiments (data not shown),
was placed in the lower chamber. Wells without IL-8 in
the lower chamber or neutrophils without any treatment
in the upper chamber were included as controls. All
experiments were run in duplicate. After co-incubation
of neutrophils with the inserts at 37°C for 2 hours, the
plates with inserts within the wells were centrifuged for
5 minutes at 50 g and 4°C to dislodge adherent neutro-
phils on the lower surface of the inserts. The cells in the
lower chamber were collected and quantified by MPO
activity assay.
Serum levels of IL-8, TNF-a, angiopoietin-1 (ANGPT-1) and
angiopoietin-2 (ANGPT-2)
Sera collected from AAV patients in remission (n =3 7 ) ,
patients with active disease (n = 18) and healthy blood
donors (n =3 0 )w e r eu s e df o rm e a s u r e m e n to fI L - 8 ,
TNF-a, ANGPT-1 and ANGPT-2. IL-8 and TNF-a
levels were measured by ELISA (R&D Systems, Minnea-
polis, MN, USA) as described previously [18]. After
sample incubation and binding of the biotinylated
detecting antibodies, color reaction was performed with
streptavidin-poly-HRP (Sanquin, Amsterdam, The Neth-
erlands) and tetramethyl-benzidin (TMB, Roth, Karls-
ruhe, Germany). Levels of angiopoietin-1 and
angiopoietin-2 in sera were measured using ELISA kits
(R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions.
Normal levels of these cytokines in serum were
defined as the mean ± 2 SD of healthy controls.
Statistical analysis
Results of CXCR1 and CXCR2 expression are presented
as medians. Serum levels of IL-8, TNF-a, ANGPT-1 and
ANGPT-2 and membrane expression of adhesion mole-
cules are presented as means. Data were analyzed by the
Mann-Whitney test and Spearman’s rank correlation
test using GraphPad Prism 4.03 (GraphPad Software,
San Diego, CA, USA). P values less than 0.05 were con-
sidered significant.
Results
Expression of CXCR1 and CXCR2 on the neutrophil
membrane is decreased in AAV
We first evaluated expression levels of CXCR1 and
CXCR2 on neutrophils in AAV patients (remission, n =
37; active, n =5 )i nc o m p a r i s o nw i t hh e a l t h yb l o o d
donors (n = 30). Both receptors were highly expressed
on the membrane of neutrophils. There was no differ-
ence in CXCR1 and CXCR2 expression in patients with
different AAV diseases or between patients with MPO-
or PR3- ANCA specificity (data not shown). Neutrophils
from patients in remission (median 1153, range 640 to
approximately 1,986) showed comparable expression of
CXCR1 as those from HC (1,163, 790 to approximately
1,790, P = 0.3), while neutrophil CXCR1 levels were sig-
nificantly decreased in patients with active disease (533,
416 to approximately 1,071) compared to either HC (P
= 0.003) or patients in remission (P = 0.0023) (Figure
1A). CXCR2 expression was significantly down-regulated
in AAV patients in remission (453, 201 to approximately
817) compared to HC (589, 290 to approximately 941, P
= 0.0004) and further decreased in active patients (323,
242 to approximately 564) as compared to HC (P =
0.0086) (Figure 1B). A significant correlation was
observed between the expression of CXCR1 and CXCR2
on neutrophils of AAV patients, regardless of disease
activity (Figure 1C, spearman r = 0.87, P < 0.0001).
IL-8 and TNF-a down-regulate CXCR1/CXCR2 from the
neutrophil membrane
IL-8 and TNF-a are proinflammatory cytokines reported
to be elevated in the serum of AAV patients [19-21].
Serum levels of ANGPT-2 have also recently been
reported to be increased in AAV and to correlate with
disease activity [22]. IL-8 is also produced by endothelial
cells stimulated with ANGPT-1 [23]. Therefore, we first
tested the influences of these cytokines on CXCR1 and
CXCR2 expression on neutrophils of HC. As a result,
both IL-8 and TNF-a down-regulated CXCR1 and
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dependent manner. IL-8, at a concentration of 5 ng/ml,
reduced CXCR2 levels to 61% compared to controls
incubated with normal medium, while IL-8 down-regu-
lated membrane expression of CXCR1 to 71% at 20 ng/
ml (Figure 2A left figure). TNF-a significantly reduced
CXCR1/CXCR2 expression already at a dose of 1 ng/ml
(Figure 2B left figure). When tested in parallel, CD177
(NB1) expression was slightly increased by IL-8 and sig-
nificantly up-regulated by TNF-a, as reported in earlier
studies [14,24]. The effects were less obvious when
neutrophils of quiescent AAV patients were used. A sig-
nificant reduction in expression of CXCR1 and CXCR2
was observed only at a concentration of 20 ng/ml of IL-
8 (Figure 2A, right figure). Incubation with TNF-a
decreased their expression but not to the same extent as
seen for HC neutrophils (Figure 2B, right figure). Possi-
bly AAV neutrophils are already pre-primed in the cir-
culation and, therefore, respond less to in vitro
treatment with cytokines. ANGPT-1 and ANGPT-2 did
not affect CXCR1/CXCR2 or CD177 expression on iso-
lated neutrophils (Figure 2C and 2D).
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Figure 1 Down-regulated expression of CXCR1 and CXCR2 on neutrophils in AAV. Levels of CXCR1 (A) and CXCR2 (B) expression on the
membrane of neutrophils were measured by flow cytometry and compared between AAV patients in remission (n = 37), AAV patients with
active disease (n = 5) and healthy controls (HC, n = 30). Expression levels are presented as MFI corrected for nonspecific binding of isotype
control antibodies on neutrophils. Horizontal lines represent medians. *, P < 0.05; **, P < 0.01 ***, P < 0.001. Correlation between CXCR1 and
CXCR2 expression (C) on neutrophils was analyzed in patients in remission and with active disease (n = 42, Spearman r = 0.87, P < 0.0001).
Dotted line represents the best-fit correlation between CXCR1 and CXCR2 expression. AAV, ANCA-associated vasculitides; ANCA, anti-neutrophil
cytoplasmic autoantibody; MFI, mean fluorescence intensity.
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AAV
Levels of the cytokines mentioned above, which may
have direct or indirect effects on CXCR1/CXCR2
expression, were evaluated in our patient cohort in com-
parison with HC.
Defining the normal range as mean ± 2SD of the IL-8
concentration in 30 healthy controls, 5 out of 37 (14%)
patients in remission and 10 out of 18 (56%) active
patients showed increased IL-8 levels. Levels of IL-8
were not significantly different between patients with
quiescent AAV (median 2.81 pg/ml, range 0.0 to
approximately 19.64 pg/ml) and healthy controls (2.30
pg/ml, 0 to approximately 15.43 pg/ml). However, a
negative correlation was present between CXCR1/
CXCR2 expression on neutrophils and levels of IL-8 in
patients in remission (Figure 3). A negative correlation
was not observed between IL-8 and CXCR1/2 in active
AAV, probably due to the small sample size. Neverthe-
less, in concert with further decreased CXCR1/2 expres-
sion, IL-8 levels increased remarkably during active
disease (8.67 pg/ml, 3.96 to approximately 51.55 pg/ml),
and were significantly higher than levels in HC and
patients in remission (Figure 4A).
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Figure 2 Down-regulation of CXCR1 and CXCR2 on neutrophils by IL-8 and TNFa. Isolated neutrophils from HC were pre-incubated with
serial doses of IL-8 (A, left figure), TNFa (B, left figure), ANGPT-1 (C) or ANGPT-2 (D). Isolated neutrophils from AAV patients were pre-incubated
with serial doses of IL-8 (A, right figure) and TNF a (B, right figure). Membrane expression of CXCR1 (black dots) and CXCR2 (black diamonds)
was measured by flow cytometry. Expression of CD177 (open dots) was measured in parallel as control for stimulation. Results are presented as
percentages compared to control incubation with normal medium (ctrl). CXCR1 and CXCR2 are equally down-regulated by TNFa (overlapping
graphs in panel B). Results are the mean (± SD) of three experiments, *, P < 0.05; **, P < 0.01 (CXCR1 and CD177). #, P < 0.01 (CXCR2). AAV,
ANCA-associated vasculitides; ANCA, anti-neutrophil cytoplasmic autoantibody; ANGPT, angiopoietin; IL; interleukin; TNF, tumor necrosis factor.
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Figure 3 CXCR1/CXCR2 expression correlates with IL-8 levels in quiescent AAV. Expression of CXCR1, CXCR2 and levels of IL-8 were
measured in parallel in patients in remission (n = 37). Membrane expression of CXCR1 and CXCR2 is presented as MFI corrected for nonspecific
binding of isotype control antibodies on neutrophils. IL-8 levels are presented as concentration in serum. A. Correlation between CXCR1
expression on neutrophils and serum levels of IL-8 (Spearman r = -0.34, P = 0.04). B. Correlation between CXCR2 expression on neutrophils and
serum levels of IL-8 (Spearman r = -0.41, P = 0.01). Dotted lines represent the best-fit correlation between expression of CXCR1/2 and IL-8 levels.
AAV, ANCA-associated vasculitides; ANCA, anti-neutrophil cytoplasmic autoantibody; IL, interleukin.
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Figure 4 Levels of IL-8, ANGPT-1 and ANGPT-2 in sera from patients with AAV. Levels of IL-8 (A), ANGPT-1 (B) and ANGPT-2 (C) in sera of
AAV patients in remission (n = 37) and active disease (n = 18) were measured by ELISA and compared to HC (n = 30). Results are presented as
the concentration of each cytokine in serum. Bars denote medians, *, P < 0.05; ***, P < 0.001. AAV, ANCA-associated vasculitides; ANCA, anti-
neutrophil cytoplasmic autoantibody; ANGPT, angiopoietin; IL; interleukin.
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was observed between HC and patients in remission.
The median level of ANGPT-1 in active patients was
lower than in HC (Figure 4B). Levels of ANGPT-2 were
not increased in patients in remission nor in patients
with active disease (Figure 4C). TNF-a was not detect-
able in sera of either HC or patient groups.
Neutrophil recruitment after CXCR1/CXCR2 blockade
To further clarify possible consequences of CXCR1 and
CXCR2 down-regulation on neutrophils, we investigated
neutrophil adhesion and transmigration through a glo-
merular endothelial monolayer. Neutrophils were pre-
treated with repertaxin, mimicking decreased efficiency
of IL-8 receptors, or stimulated with IL-8/TNF-a, both
of which lead to decline of CXCR1 and CXCR2
expression.
Glomerular endothelial cell layers were stimulated
with 10 ng/ml of TNF-a for 4 hours prior to the adhe-
sion or migration assay to mimic activated glomerular
endothelial cells as occur in AAV. Preincubation with
repertaxin inhibited neutrophil migration in a dose-
dependent way. Migration was reduced to 76% by 100
nM of repertaxin, significantly lower than control incu-
bated neutrophils. IL-8 preincubation reduced the num-
ber of migrated neutrophils to 39%. Although
incubation with TNF-a resulted in a significantly
reduced expression of CXCR1/CXCR2 on the mem-
brane of neutrophils, migration was not significantly
influenced, and numbers of migrated neutrophils were
comparable with control incubation (Figure 5B).
Neutrophils preincubated with 2 ng/ml TNF-a
showed enhanced adhesion to glomerular endothelium
compared to control incubation. IL-8 (up to 20 ng/ml),
however, did not show a remarkable effect on neutrophil
adhesion. Blocking CXCR1 and CXCR2 with repertaxin
also increased the number of adherent neutrophils dose-
dependently, from 135% with 10 nM of repertaxin up to
more than 300% at 0.5 μM as compared to cells without
stimulation (Figure 5A).
Discussion
This is the first study, to our knowledge, reporting
decreased expression of CXCR1 and CXCR2 on circulat-
ing neutrophils in AAV, potentially induced by proin-
flammatory cytokines such as IL-8. Functional
deficiency of CXCR1/CXCR2, induced by specific inhibi-
tion of these receptors with repertaxin, increased neu-
trophil adhesion and impaired migration through a
glomerular endothelium monolayer. Down-regulation of
CXCR1 and CXCR2 may retain activated neutrophils
within the vessel wall, allowing interaction with circulat-
ing ANCA, so leading to vascular damage in situ. These
findings highlight a chemokine-receptor-based mechan-
ism of inflammation confined within the vessel wall and
would further explain the role of neutrophils in the
pathogenesis of AAV.
CXCR1 and CXCR2 are not stably expressed on the
neutrophil membrane. During chemotaxis, ligand-
mediated internalization and recycling of these chemo-
kine receptors is proposed as a self-limiting mechanism
allowing neutrophils, to retain in situ by desensitization
to their ligands[25]. However, this physiological process
is probably abused in AAV, and down-regulated
CXCR1/CXCR2 expression may desensitize circulating
neutrophils to chemotactic signals before they migrate
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Figure 5 CXCR1/CXCR2 blockade enhances neutrophil adhesion and inhibits neutrophil transmigration through an endothelial cell
monolayer. Isolated neutrophils from HC were pre-incubated with serial doses of repertaxin, IL-8 (10 ng/ml) or TNFa (2 ng/ml) before being
loaded onto a glomerular endothelial monolayer or a transwell insert. After co-incubation of pretreated neutrophils with glomerular endothelial
cells for 30 minutes for the adhesion assay (A, n = 5) or with transwell inserts coated with endothelial cells for 2 hours (B, n = 6), the number of
adherent or migrated neutrophils were quantified by MPO activity assay. Results are presented as the percentages of adherent or migrated
neutrophils after stimulation compared to control incubation. *, P < 0.05. HC, healthy control; IL; interleukin; MPO, myeloperoxidase; TNF, tumor
necrosis factor.
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within the vessel wall.
Our in vitro experiments confirmed this hypothesis by
showing significantly increased adhesion and decreased
migration of neutrophils through glomerular endothe-
lium after CXCR1 and CXCR2 blockade. This is in line
with our previous observation that, in a model of MPO-
ANCA-associated vasculitis, repertaxin treated mice
were not protected from hematuria, albuminuria or glo-
merular crescent formation. Although some neutrophil
migration through the endothelial monolayer in our in
vitro experiments can not completely be ruled out, we
observed a larger number of neutrophils accumulating
in glomeruli in comparison to untreated mice [26].
Besides, CXCR1/CXCR2-knockout mice showed a defi-
ciency in neutrophil migration and bacterial clearance in
a urinary tract infection model, and decline in CXCR1/
CXCR2 expression may worsen outcome of infections
due to impaired neutrophil recruitment [27-31].
Notably, down-regulation of CXCR1 and CXCR2 from
the neutrophil surface may not be specific for AAV. As
IL-8 is a potential inducer of decreased CXCR1/2
expression, increased levels of circulating IL-8 in other
clinical conditions may also result in a similar decline of
CXCR1/2 expression. In addition, our results may reflect
a state of neutrophil activation mediated by IL-8 or
other proinflammatory cytokines, such as TNFa,a sh a s
been described in AAV by Muller Kobold et al. pre-
viously [32]. In the presence of ANCA, however, pre-
activated neutrophils lacking CXCR1/2 expression can
be confined in the microvasculature and fully activated
by ANCA.
T h er o l eo fC X C R 1a n dC X C R 2i nn e u t r o p h i la d h e -
sion has not been clearly delineated. Blocking of IL-8-
receptors showed an inhibitory effect on IL-8-induced
neutrophil adhesion in an early study [33]. The underly-
ing mechanisms are not fully elucidated so far. A recent
study conducted by Cohen-Hillel et al. showed that
migratory desensitization triggers over-activation of
focal adhesion kinase (FAK), which leads to increased
neutrophil adhesion [34]. The latter mechanism is likely
operative in AAV, where neutrophils are migratory
desensitized under continuous exposure to low-dose IL-
8 [20]. Besides, in our experiments, neutrophils pre-
treated with repertaxin did show significantly increased
adhesion on an activated CiGEnC monolayer. As
endothelial cells might also be actively involved in neu-
trophil-endothelial interaction during inflammation, this
adhesive effect may also depend on endothelial pheno-
types and microenvironment, explaining why Coelho et
al. observed short-term suppression of neutrophil adhe-
sion to synovial endothelium after repertaxin treatment
in a mouse model of arthritis [35]. Glomerular endothe-
lial cells (ECs) have unique features and differ from
synovial ECs in many ways, such as expression profile of
adhesion molecules [36]. Neutrophil recruitment in an
in vitro model of rheumatoid arthritis only occurs in co-
cultures of ECs with synovial fibroblasts but not with
control tissues [37], suggesting that immune regulators
in the microenvironment also play an important role in
this process. We are aware of the fact that the cells used
in our study were glomerular endothelial cells that were
immortalized, and therefore seem artificial. However
these cells were shown to have retained morphological
features of early-passage primary culture glomerular ECs
and they expressed EC adhesion molecules and other
specific features [13].
Since CXCR1 and CXCR2 are internalized upon liga-
tion and IL-8 has been shown to be significantly ele-
vated in AAV patients [20], we speculate that IL-8 is
one of the factors inducing decreased expression of
these receptors. Indeed, we found that CXCR1 and
CXCR2 expression was remarkably lower in patients
with active AAV than in HC. Decreased expression was
accompanied by significantly elevated serum levels of
IL-8 in active AAV. Moreover, a negative correlation
was observed between CXCR1/CXCR2 expression and
serum IL-8 levels in patients with quiescent disease. As
an indirect evidence of this relationship, a negative effect
of serum IL-8 on neutrophil recruitment has been
demonstrated in earlier studies which was supposed to
be caused by down-regulation of IL-8 receptors [38,39].
Cockwell et al. proposed a similar scenario in AAV by
showing that ANCA-activated neutrophils produce IL-8
and that neutrophils accumulate locally in the glomeru-
lar capillary loops but poorly penetrate into IL-8
enriched tissues as observed in renal biopsies of AAV
patients [40]. From the data of the present study, a rela-
tionship is suggested between circulating IL-8 levels,
decrease in CXCR1/CXCR2 expression and neutrophil
accumulation in the microvasculature in AAV.
Circulating IL-8 can be produced by ANCA-activated
neutrophils and endothelial cells stimulated by IL-1,
TNF-a or PR3-ANCA [40-42]. Although circulating IL-
8 levels were not significantly elevated in patients during
remission, it should be noted that a low-level of immune
activation is present during quiescent disease as well,
including minor increases in IL-8 levels [43].
CXCR1 and CXCR2 expression can also be regulated,
via enzymatic cleavage via metalloproteinases [44], by
other immunomodulators such as TNF-a which have
been detected at inflammatory sites in AAV and prime
neutrophils for ANCA-induced activation [20,45-47].
Technical limitations to measure TNFa in serum could
have hampered the revelation of the relationship
between TNFa levels and CXCR1/2 expression. As
shown in the current study, TNF-a, up to a concentra-
tion of 20 ng/ml, was more efficient than IL-8 in down-
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Page 9 of 11regulating CXCR1/CXCR2 in vitro. Therefore, although
TNF-a could not be detected in sera, there is still the
possibility that increased levels of TNF-a, especially dur-
ing active disease, lead to a decrease in CXCR1 and
CXCR2 expression.
It needs to be mentioned that the number of patients
with active AAV included in the current study was rela-
tively small, and so does not allow firm conclusions as
to the correlation between neutrophil CXCR1 and
CXCR2 expression and disease activity. Such a correla-
tion is, however, suggested by the further decrease of
CXCR1 and CXCR2 expression that we observed during
active disease. Furthermore, immunohistochemical stu-
dies are needed to show lack of CXCR1 and CXCR2
expression on neutrophils recruited to the vascular wall
in AAV. Such data could further strengthen the role of
CXCR1 and CXCR2 down-regulation in AAV.
Conclusions
Expression of CXCR1 and CXCR2 on neutrophils is
down-regulated in AAV patients, potentially induced by
circulating IL-8. Decreased expression of these chemo-
kine receptors may enhance neutrophil adhesion and
impede neutrophil migration through activated glomeru-
lar endothelium, which may account for neutrophil
accumulation and persistent ANCA-induced inflamma-
tion in the vessel wall.
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